Dan-Arin Silasi, MD

Associate Professor of Obstetrics, Gynecology, and Reproductive Sciences; Director, 'Discovery to Cure' International Fellowship Program in Gynecologic Oncology; Director, Obesity Robotic Pelvic Surgery Program

Clinical Interests

  • Antineoplastic Combined Chemotherapy Protocols
  • Pelvic Exenteration
  • Pelvic Neoplasms
  • Chemotherapy, Cancer, Regional Perfusion
  • Laparoscopy
  • Precancerous Conditions
  • Gynecologic Surgical Procedures
  • Chemotherapy, Adjuvant
  • Neoadjuvant Therapy
  • Robotic Surgical Procedures
  • Cytoreduction Surgical Procedures

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Adolescent; Child; Geriatric
Referrals: From patients or physicians

Patient Care Organizations

Obstetrics, Gynecology & Reproductive Sciences: Discovery to Cure | Gynecologic Oncology: Ovarian Cancer Early Detection Program | Women's Reproductive Cancers Program

Yale Cancer Center: Gynecologic Oncology Program

Yale Medicine

Office of Cooperative Research

Clinical Trials

Conditions Study Title
Ovary Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Ovary A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Other Female Genital A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Ovary A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Ovary An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Corpus Uteri A phase II evaluation of pembrolizumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent hypermutated/ultramutated endometrial cancer identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP), A Pilot Study
Other Female Genital, Other Urinary, Ovary A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cervix Uteri Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
Bladder, Other Urinary, Phase I A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Ovary A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens
Corpus Uteri Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Other Female Genital A Phase II Evaluation of Afatinib
Ovary Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Bladder, Breast - Female, Cervix Uteri, Corpus Uteri, Ovary Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers

Edit this profile

Contact Info

Dan-Arin Silasi, MD
Patient Care Locations
Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 1st floor

New Haven, CT 06511
View on map...
Yale Gynecologic OncologyStamford Hospital
30 Shelburne Road

Stamford, CT 06902
View on map...
Mailing Address
PO Box 208063
New Haven, CT 06520-8063